Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment

This trial tests nivolumab, an immunotherapy drug, in patients with nasopharyngeal cancer (a cancer of the upper part of the throat, behind the nose) that has progressed during or after platinum-based chemotherapy. Nivolumab works by removing the "brakes" on the immune system, allowing it to attack cancer cells. **You may be eligible if...** - You are over 18 with confirmed squamous cell carcinoma of the nasopharynx - Your cancer has come back or spread during or within 6 months after platinum-based chemotherapy - Your overall health score is acceptable (ECOG 0–1) - Your kidney, liver, and blood function meet minimum requirements **You may NOT be eligible if...** - You have active cancer spread to the brain - You have significant kidney problems (low filtration rate) - You have significant liver dysfunction or low blood counts (anemia, low platelets, or low neutrophils) - Your heart's pumping function is less than 50% on an echocardiogram - You have an active autoimmune disease (exceptions: treated thyroid disease or type 1 diabetes) Talk to your doctor to see if this trial is right for you.